Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer.[4][5] It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer.[7][8] Sotorasib is an inhibitor of the RAS GTPase family.[4]
The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.[4][5]
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers.[5] KRAS G12C mutations occur in about 13% of patients with non-small cell lung cancers.[5] Sotorasib was approved for medical use in the United States in May 2021,[5][9] and in the European Union in January 2022.[6] The US Food and Drug Administration considers it to be a first-in-class medication.[10]
^ ab"Lumakras APMDS". Therapeutic Goods Administration (TGA). 13 April 2022. Archived from the original on 12 April 2022. Retrieved 23 April 2022.
^"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
^"Summary Basis of Decision (SBD) for Lumakras". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
^ abcd"Lumakras- sotorasib tablet, coated". DailyMed. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
^ abcdef"FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy". U.S. Food and Drug Administration (FDA). 28 May 2021. Archived from the original on 28 May 2021. Retrieved 28 May 2021. This article incorporates text from this source, which is in the public domain.
^ abCite error: The named reference Lumykras EPAR was invoked but never defined (see the help page).
^"KRAS mutant-targeting AMG 510". NCI Drug Dictionary. National Cancer Institute. 2 February 2011. Archived from the original on 10 July 2019. Retrieved 16 November 2019.
^Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. (November 2019). "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity". Nature. 575 (7781): 217–223. Bibcode:2019Natur.575..217C. doi:10.1038/s41586-019-1694-1. PMID 31666701. S2CID 204969251.
^Cite error: The named reference CNBC 20210528 was invoked but never defined (see the help page).
^Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer. It targets a specific...
designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation. In May 2021, sotorasib received accelerated...
adenocarcinomas (PDACs) have a KRAS mutation. There is one approved drug, sotorasib, that targets the KRAS G12C mutation, but only ~1% of PDACs have this...
Global Information
This article incorporates text from this source, which is in the public domain.
